Inactivation of the most important tumour suppressor gene TP53 occurs in most, if not all,
human cancers. Loss of functional wild-type p53 is achieved via two main mechanisms …

Proteolysis Targeting Chimeras (PROTACs), an emerging therapeutic entity designed to
degrade target proteins by hijacking the ubiquitin–proteasome system, have the potential to …

Abstract Chaperone-mediated autophagy (CMA), a proteolytic system contributing to the
degradation of intracellular proteins in lysosomes, is upregulated in tumors for pro …

Background Although anti-programmed cell death protein 1 (PD-1) immunotherapy is
greatly effective in melanoma treatment, low response rate and treatment resistance …

Abstract Treatment for chronic diabetic wounds remains a clinical challenge. Wound healing
process occurs in three phases: inflammation, proliferation and remodeling. Several factors …

Introduction Chirality is immanent in nature, and chiral molecules can achieve their
pharmacological action through chiral matching with biomolecules and molecular …

Breast cancer is becoming one of the main lethal carcinomas in the recent era, and its
occurrence rate is increasing day by day. There are different breast cancer biomarkers, and …

Herein, density functional theory (DFT) calculations were employed to evaluate the
performance of a drug delivery system for cysteine amino acid functionalized carbon nitride …

Significant progress in nanotechnology has enormously contributed to the design and
development of innovative products that have transformed societal challenges related to …

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of
the ubiquitin-proteasome-system has become a promising strategy in drug design. The …